Treatment of Staphylococcus aureus infections utilizing antibodies that bind to fibronectin binding proteins

• US 8,211,432 B2
• Filed: 10/31/2006
• Issued: 07/03/2012
• Est. Priority Date: 01/21/1997
• Status: Expired due to Term

• Current Assignee: Universita' Degli Studi Di Pavia (Repubblica Italiana), Texas A&M University System, University of Manitoba
• Original Assignee: Universita' Degli Studi Di Pavia (Repubblica Italiana), Texas A&M University System, University of Manitoba
• Inventors: Höök, Magnus, Patti, Joseph M., Speziale, Pietro, Joh, Danny, McGavin, Martin J., House-Pompeo, Karen L.
• Primary Examiner(s): Zeman, Robert A
• Application Number:
  US11/589,760
• Publication Number:
  US 20070110748A1
• Time in Patent Office: 2,072 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/085 Staphylococcus
• CPC Class Codes: A61K 39/092 Streptococcus
• CPC Class Codes: C07K 14/31 from Staphylococcus (G)
• CPC Class Codes: C07K 14/315 from Streptococcus (G), e.g. Enterococci
• CPC Class Codes: C07K 16/1271 from Micrococcaceae (F), e.g. Staphylococcus
• CPC Class Codes: C07K 16/1275 from Streptococcus (G)
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/54 F(ab')2
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: G01N 2333/31 from Staphylococcus (G)
• CPC Class Codes: G01N 2333/315 from Streptococcus (G), e.g. Enterococci
• CPC Class Codes: G01N 2333/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: G01N 33/6887 from muscle, cartilage or connective tissue

Abstract

Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnbA and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments encoding these peptides and epitopes. The anti-(fibronectin binding site) antibodies, peptides and epitopes that give rise to antibodies that block the binding of fibronectin binding proteins to fibronectin, and DNA segments encoding these proteins and are of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of streptococcal and staphylococcal colonization in animals or humans. These. DNA segments and the peptides derived therefrom are proposed to be of use directly in the preparation of vaccines and also for use as carrier proteins in vaccine formulations.

Claims

1. A method of treating a Staphylococcus aureus infection in a human or animal, comprising administering to said human or animal a therapeutically effective amount of an antibody that is generated against a peptide selected from the group consisting of SEQ ID NOS:

2, 4, 6, 8, 10, 12-55, 57, 59-86 and 88-105.

2. The method of claim 1, wherein said antibody is administered with a pharmaceutically-acceptable vehicle, diluent, or excipient.

3. The method of claim 1, wherein said antibody is administered to a human or animal suspected of having a Staphylococcus aureus infection.